Plastic/Elastomeric Materials for Pharmaceutical Packaging and Production

25/26 September 2019, Barcelona, Spain

Course No. 16440



Torsten Kneuss

Torsten Kneuss


Dr Bettine Boltres

Dr Bettine Boltres

West Pharmaceutical Services


This conference deals with the development, manufacture, use and control of plastic/ elastomeric materials for medicinal products, medical devices & combination products and for use in manufacturing. The conference gives you an update on the U.S., E.U. and Chinese regulatory requirements and shows you how these requirements can be put into practice. One of the focus topics is the use of additives as well as their testing and assessment by means of extractables/leachables studies. You also get the latest information on child-resistant packaging. And the conference subjects are rounded off from a GMP compliance point of view with the topics testing of plastic/elastomeric materials and handling of plastic/elastomeric materials during manufacturing.


European Requirements on the development, testing and registration of plastic materials can among others be found in the EMA „Guideline on Plastic Immediate Packaging Materials”. U.S. requirements are laid down in the FDA Guidance for Industry „Container Closure Systems for Packaging Human Drugs and Biologics“. In Addition, since reforms of the existing Chinese regulations started as from mid 2016 on, it has become a really hot topic for pharma industry.
The EMA guideline covers the specific requirements (data to be submitted) for plastic packaging materials intended to be in direct contact with the medicinal product or the API. The guideline has to be applied in new registration applications or in variation applications. However, the guideline does not cover requirements for elastomeric components. In Addition, the EU regulation 10/2011 on plastic materials and articles intended to come into contact with food also deals with plastic materials but not with elastomeric materials.

According to the FDA guideline, each application should contain enough information to show that each proposed container closure system and its components are suitable for its intended use. This includes:
  • Protection (light exposure, oxygen, moisture permeation, leakage)
  •  Compatibility
  •  Safety (extraction/toxicological evaluation studies)
  •  Performance (container closure system functionality, drug delivery)
Today, new requirements are coming up, since there are currently many medical devices and combination products (e.g. pre-filled syringes) on the market. These devices sometimes contain materials currently not monographed by the pharmacopoeias (for example COC and COP). And: Are there any requirement for plastic materials (e.g. tubes) used in the manufacture of pharmaceutical drug products and biopharmaceuticals? This conference presents updates on the regulatory requirements on these materials. There are currently a lot of pharmacopoeial changes/developments going on, e.g. recent drafts for USP General Chapters:
  • <382> Elastomeric Component Functional Suitability in Parenteral Products Packaging /Delivery Systems,
  • <1381> Assessment of Elastomeric Components Used in Injectable Pharmaceutical Product Packaging/Delivery Systems,
  • <1382> Assessment of Elastomeric Component Functional Suitability in Parenteral Products Packaging /Delivery Systems.
These 4 chapters were published in Pharmacopeial Forum (PF) 43(3) [May–Jun. 2017]. Revised drafts  have recently been pre-published on the USP website. According to the USP, the proposed revisions will be published in Pharmacopeial Forum (PF) 45(4) [Jul.–Aug. 2019]. The objective of this pre-posting is to give stakeholders sufficient time to review the proposals and comment by September 30, 2019. In the absence of any adverse comments the chapters are anticipated to be published in USP 43-NF 38, Second Supplement (the targeted official date is December 1, 2020).

In a recent issue of Pharmacopeial Forum (PF 45(2) [March–April 2019]) the following general chapter have been re-published for comment
  •  <661> Plastic Packaging Systems and Their Materials of Construction,
  •  <661.1> Plastic Materials Of Construction,
  •  <661.2> Plastic Packaging Systems for Pharmaceutical Use,
  •  <1661> Evaluation of Plastic Packaging Systems and Their Materials of Construction With Respect to Their User Safety Impact,
  •  <665> Plastic Materials, Components, and Systems Used in the Manufacturing of Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products,
  •  <1665> Characterization of Plastic Materials, Components, and Systems Used in the Manufacturing of Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products.
According to the new draft for <661.1> “it is being left up to the material user to evaluate the need for extractable elements testing and, if such testing is necessary, to establish and justify the means by which testing is accomplished”.

Furthermore Ph. Eur. Draft Chapters on “new” plastic/ elastomeric materials like, for example, COC/ COP (Cyclo-olefin Polymer) and SBC are expected to be published soon:
  • 3.1.17 Cyclo-olefin copolymers (COC),
  • 3.1.18 Styrene block copolymers (SBC) for containers and closures for parenteral and ophthalmic preparations.
This conference provides an excellent forum to discuss open questions regarding the ongoing developments directly with speakers from industry, regulators and members of the pharmacopoeial expert working groups!

Target Group

The conference is especially designed for members of staff and executives from the pharmaceutical industry working in the field of research and development, regulatory affairs, quality control, incoming goods control of packaging materials, quality assurance, production and packaging. It is also directed at employees of suppliers and/or manufacturers of plastic/elastomeric (packaging) materials for the pharmaceutical industry.

Free PDF-Download - exclusive for Participants

Defect Evaluation List for Rubber Parts, New Edition 2019!

Checklists and instructions for use in the testing of packaging material


Introduction into Plastic and Elastomeric Materials and Manufacturing of Elastomeric Materials
  •  Scientific Background of plastics and elastomers
  •  Relevant physical properties and their impact on product quality
  •  Overview of manufacturing process for elastomers
U.S. Regulatory Requirements for Plastic/ Elastomeric Materials
  •  General regulatory requirements
  •  FDA Guidance on Container Closure Systems
  •  Update of Compendial Standards: relevant USP General Chapter
E.U. Regulatory Requirements for Plastic/ Elastomeric Materials
  •  General regulatory requirements
  •  EMA Guideline on plastic immediate packaging materials
  •  Update of Compendial Standards: relevant Ph. Eur. General Chapter
Chinese Regulatory Requirements for Plastic/ Elastomeric Materials
  •  Update on Chinese regulations started as from mid 2016 on
Specific Requirements for Plastic/ Elastomeric Materials
  •  When is a material of pharmacopoeial quality?
  •  Material selection criteria
  •  Material properties and design
  •  Example: Prefilled plastic syringes made of COC and COP
Polymer Additives in Plastic / Elastomeric Materials
  •  Types of additives
  •  Their mode of action
  •  Use
  •  Function
  •  Physical Behaviour
USP <665>: Polymeric components and systems used in the manufacturing of pharmaceutical and biopharmaceutical drug products
  • Drivers for Innovative Manufacturing
  • Risk Assessment for Manufacturing Systems
  • USP <665>
  • Our Strategy
Supplier Qualification – A Risk based Approach
  •  Quality agreement
  •  Supplier review
  •  Applicable Standards
  •  Risk-based qualification
Extractables / Leachables (E&Ls)
  •  Regulatory Requirements
  •  When is Extractable testing necessary?
  •  Best Practices for E&L testing
  •  Which components could be potential E&Ls?
  •  Case Study
Manufacturing of Plastic Materials (and Handling in the Warehouse)
  •  Storage
  •  Processing
  •  IPC and Reconciliation
  •  Shopfloor requirements
  •  Blister integrity testing
Quality Control of Plastic/ Elastomeric Materials
  •  Specifications
  •  Sampling plans, AQLs (Acceptable Quality Levels) and DELs (Defect Evaluation Lists)
  •  Common test methods
  •  Challenges
Child-resistant Packaging
  •  Definition
  •  Testing procedures
  •  Child resistance vs. Senior friendliness
  •  Examples


This course is part of the GMP Certification Programme "ECA Certified Packaging Manager" Learn more

ECA-Member*: € 1690,-
Non ECA Member*: € 1890,-
EU/GMP Inspectorates*: € 945,-
APIC Member Discount*: € 1790,-

(All prices excl. VAT). Important notes on sales tax.

* also payable by credit card
American Express Visa Mastercard

Further dates on-site
Further dates on-site
Not available
Further dates online
Further dates online
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0

Woman with headset

Go back

Testimonials about our courses and conferences

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023


“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024


“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024



“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023